Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06703021 · ClinicalTrials.gov registry record · Phase 2

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

A Phase 2 study of Obesity and Overweight, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.

Active
Registry status
Phase 2
Development phase
82
Enrollment target
10
Study locations

NCT06703021 is a Phase 2 study of Obesity and Overweight that is active but no longer recruiting, run by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. The registered enrollment target is 82 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06703021, a Phase 2 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
82 participants
Enrollment target
10
Study locations

Study Summary

Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.

Conditions Studied

Obesity Overweight Chronic Weight Management

Interventions

  • DRUG aleniglipron or placebo

Study Locations (10)

California

  • ACCESS II Research Site - Glendale
  • ACCESS II Research Site - Montclair

Texas

  • ACCESS II Research Site - Dallas
  • ACCESS II Research Site - San Antonio

Indiana

  • ACCESS II Research Site - Valparaiso

Iowa

  • ACCESS II Research Site - West Des Moines

Oregon

  • ACCESS II Research Site - Medford

Rhode Island

  • ACCESS II Research Site - East Greenwich

South Carolina

  • ACCESS II Research Site - North Charleston

Utah

  • ACCESS II Research Site - West Jordan

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2024-12-20
Est. Completion 2025-12
Phase Phase 2

Sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06703021

The ClinicalTrials.gov registry entry for NCT06703021 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (90% lower). The listed sponsor is Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which aleniglipron or placebo is the first listed.

NCT06703021 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Texas, Indiana.

Frequently Asked Questions

What is clinical trial NCT06703021 about?

NCT06703021 is a clinical study titled "A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity". Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 4...

What is the current status of trial NCT06703021?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2024-12-20. Estimated completion is 2025-12.

What conditions does trial NCT06703021 study?

This clinical trial studies the following conditions: Obesity, Overweight, Chronic Weight Management.

What interventions are being tested in trial NCT06703021?

The interventions under investigation include: aleniglipron or placebo (DRUG).

Who is sponsoring clinical trial NCT06703021?

This trial is sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06703021 being conducted?

This trial has 10 study locations across California, Indiana, Iowa, Oregon, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.